Compositions, methods and uses for alpha-1 antitrypsin fusion molecules

Abstract

Embodiments herein report compositions of alpha-1 antitrypsin fusion polypeptides or peptide derivatives thereof. In certain embodiments, compositions and methods relate to generating a construct of use in pharmaceutically acceptable compositions to treat a subject in need of alpha-1 antitrypsin therapy or treatment. In other embodiments, compositions and methods disclosed herein concern linking alpha-1 antitrypsin or derivative thereof to an immune fragment.

What is claimed: 
     
       1. A nucleic acid construct comprising:
 a polynucleotide encoding an alpha-1 antitrypsin (AAT) polypeptide fragment wherein the AAT polypeptide fragment consists of the polypeptide sequence represented by SEQ ID NO:34; a polynucleotide encoding a linker; and a polynucleotide encoding an immunoglobulin Fc polypeptide of IgG2, IgG3, IgG4, or IgD. 
 
     
     
       2. A nucleic acid construct comprising the construct encoding the fusion polypeptide of SEQ ID NO:48. 
     
     
       3. An isolated vector comprising the nucleic acid construct of  claim 1 . 
     
     
       4. An isolated cell comprising the vector of  claim 3 . 
     
     
       5. A nucleic acid construct comprising a polynucleotide encoding an alpha-1 antitrypsin (AAT) polypeptide fragment wherein the alpha-1 antitrypsin (AAT) polypeptide fragment consists of the polypeptide sequence represented by SEQ ID NO:31, a polynucleotide encoding a linker; and a polynucleotide encoding an immunoglobulin Fc polypeptide of IgG2, IgG3, IgG4, or IgD. 
     
     
       6. The nucleic acid construct of  claim 5 , wherein immunoglobulin Fc polypeptide is IgG4 Fc.